Drug price hikes would have been impossible under pending bipartisan legislation backed by White House, Democrats

The latest round of increases in the list prices of drugs highlights how pending bipartisan legislation could force biopharma companies to rethink their business models.

In what has become a

Read the full 307 word article

User Sign In